Nisha Varghese, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1427137223
Payments from drug & device makers
Across 143 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$312
- Abbott$292
- Lilly USA, LLC$284
- AbbVie$180
- Insulet Corporation$149
- Dexcom, Inc.$143
- plus $897 from 25 others
What the payments were for
- Food & beverage$2,24699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $312 |
| Abbott | 19 | $292 |
| Lilly USA, LLC | 18 | $284 |
| AbbVie | 11 | $180 |
| Insulet Corporation | 10 | $149 |
| Dexcom, Inc. | 8 | $143 |
| Sanofi-aventis U.S. LLC | 5 | $102 |
| Amgen(2 entities) | 4 | $85 |
| Radius Health, Inc. | 5 | $75 |
| Amneal Pharmaceuticals LLC | 5 | $73 |
| Zealand Pharma US, Inc. | 4 | $62 |
| Vistapharm, Inc. | 4 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| IBSA Pharma Inc. | 3 | $38 |
| Pfizer | 2 | $34 |
| Bayer | 2 | $31 |
| AstraZeneca(2 entities) | 2 | $30 |
| Corcept Therapeutics | 2 | $26 |
| Johnson & Johnson | 2 | $26 |
| BETA Bionics, Inc. | 2 | $26 |
| Cequr Corporation | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Medtronic | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $17 |
| GRT US Holding, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Senseonics, Incorporated | 1 | $10 |
How this compares
$2,257 in reported general payments places this provider in the 30th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $222,966 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 106 | $155,749 |
| FarxigaDapagliflozin Propanediol | 150 | $141,742 |
| MounjaroTirzepatide | 86 | $115,865 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 100 | $98,500 |
| TrulicityDulaglutide | 61 | $93,673 |
| Tresiba Flextouch U-100Insulin Degludec | 114 | $83,700 |
| JardianceEmpagliflozin | 56 | $75,531 |
| Xigduo XrDapaglifloz Propaned/Metformin | 81 | $74,053 |
| RybelsusSemaglutide | 31 | $57,841 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $40,482 |
| TradjentaLinagliptin | 46 | $37,038 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $36,437 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 48 | $36,306 |
| SynthroidLevothyroxine Sodium | 368 | $34,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $312 | $293,920196 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Synjardy | $12 | $218,206214 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $209,538147 claims |
| AstraZenecaFarxiga | $30 | $141,742150 claims |
| AbbVieSynthroid | $180 | $34,529368 claims |
| IBSA Pharma Inc.Tirosint | $38 | $12,03929 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $102 | $10,64612 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $73 | $5,112287 claims |
| PfizerLevoxyl | $34 | $3,53967 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Harold BaysLouisville$12.9M
- Hisham AlrefaiLouisville$720K
- Sathya KrishnasamyLouisville$263K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Sri Prakash MokshagundamLouisville$73K
- Stephen WintersLouisville$21K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.